Latest Stock Research & Market Analysis
Search All Research, Articles & Stock Profiles
ASX Stock Research
[BUY] Nick Scali (ASX: NCK): Margins, Growth and a Franked Yield
Institutional sell-side rates Nick Scali a Buy with a 12-month price target of around A$20. The stock closed at approximately A$14.47 on 9 May 2026, implying roughly 38 per cent upside before dividends. The thesis is built on three pillars: ANZ gross margins that sit...
[BUY] ResMed (ASX: RMD) – A New Product Cycle and a Cheap Multiple
ResMed reported its 3Q26 result this week. We are reiterating our Buy view on the stock with a price target of A$46.20, against a closing price of A$28.73 on 1 May 2026 and roughly 60.8 per cent upside to that target. The thesis is straightforward. Top-line growth...
[SELL] Macquarie Group (ASX: MQG) Why a 21% Rally Into Earnings Looks Stretched
Macquarie has rallied more than 21% in the past month, pushing the multiple to 24x forward earnings against a 10-year average of 16x. We walk through why the valuation looks stretched, the bull-case rebuttals (Aligned Data Centers, Qube), and why FY26 result on 8 May is the decision point.
[SELL] Macquarie Group (ASX: MQG) Why a 21% Rally Into Earnings Looks Stretched
Macquarie has rallied more than 21% in the past month, pushing the multiple to 24x forward earnings against a 10-year average of 16x. We walk through why the valuation looks stretched, the bull-case rebuttals (Aligned Data Centers, Qube), and why FY26 result on 8 May is the decision point.
[BUY] PWR Holdings (ASX: PWH) – De-risked and Returning to Growth
PWR Holdings (ASX PWH) - De-risked and Returning to Growth PWR Holdings (ASX: PWH) designs and manufactures advanced cooling solutions for the world's most demanding...
Global Marco and Market Research
The Australian Consumer Was Already Last in the G10 on Spending. The RBA Hiked Anyway.
The G10 consumer dashboard puts Australian household spending growth dead last in the developed-market cohort. Tuesday’s RBA hike to 4.35 percent continues the squeeze. What that means for a domestic portfolio.
The Q1 CPI Was Mixed. The RBA Still Has to Hike on Tuesday.
The Reserve Bank Board meets on Monday and Tuesday next week with a rate decision at 2:30pm AEST on Tuesday. This is the most anticipated single-meeting call we have had in nine months. The case rests on a Q1 CPI print released on Wednesday that did two things at...
Why the Iran Oil Shock Points to More RBA Hikes, Not Fewer
The default narrative around the Iran conflict and the oil spike that has followed it is that it is bad news, full stop. Higher energy costs feed into inflation, dent consumer spending, and put pressure on central banks to either hold tight or cut rates to cushion the...
Global Stock Research
[BUY] Upwork (NASDAQ: UPWK) – Restructuring Sharpens the Margin Story
Upwork delivered a Q1'26 result that landed on the right side of a bifurcated narrative. Revenues came in around the midpoint of guidance at $195mn, while Adj. EBITDA of $57mn came in nearly 24% above consensus expectations, with the margin beat tracing back to a cost...
[BUY] Eli Lilly (LLY): Foundayo Reframes the Oral GLP-1 Story
LLY Buy with ~37% upside to ~US$1,283. 1Q26 EPS US$8.55 beat US$6.77, 2026 guide raised to US$82-85bn. Foundayo oral GLP-1 hits 8k prescribers in 3 weeks, 80% new incretin patients.
[HOLD] Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028
Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028 Tesla just delivered a first quarter result that was stronger than the market expected, with revenue beating the Street, automotive gross margins running well ahead of forecast, and energy storage...
[HOLD] Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028
Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028 Tesla just delivered a first quarter result that was stronger than the market expected, with revenue beating the...
[BUY] Corvus Pharmaceuticals (CRVS) – Novel and Differentiated Contender in Auto-Immune and Hematology
Corvus Pharmaceuticals has developed soquelitinib, a first-in-class oral ITK inhibitor targeting moderate-to-severe atopic dermatitis and relapsed/refractory peripheral T cell lymphoma. We initiate at Buy with a 12-month price target of $40.
Region & Industry Outlook
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
ASX Announcement
Paladin Energy (ASX: PDN) – S&P DJI June 2026 Quarterly Rebalance
Paladin Energy Limited has been elevated to the S&P/ASX 100 Index effective June 22, 2026, replacing Metcash Limited in the quarterly rebalance announced by S&P Dow Jones Indices. The move represents formal recognition of Paladin's expanded market capitalisation and...
FINEOS Corporation Holdings plc (ASX: FCL) – Included in S&P DJI June 2026 Rebalance
FINEOS Corporation Holdings plc has been removed from the S&P/ASX All Technology Index, effective from the open of trading on Monday, June 22, 2026. The removal follows the June quarterly rebalance announced today by S&P Dow Jones Indices and occurs alongside exits by...
Temple & Webster Group (ASX: TPW) – S&P DJI June 2026 Quarterly Rebalance
Temple & Webster Group Limited has been removed from the S&P/ASX 200 Index effective prior to the open of trading on Monday, June 22, 2026, as part of S&P Dow Jones Indices' quarterly rebalance announced today. The decision marks a significant development for the home...
Temple & Webster Group (ASX: TPW) – S&P DJI June 2026 Quarterly Rebalance
Temple & Webster Group Limited has been removed from the S&P/ASX 200 Index effective prior to the open of trading on Monday, June 22, 2026, as part of S&P Dow Jones Indices'...
IDP Education (ASX: IEL) – S&P DJI June 2026 Quarterly Rebalance
IDP Education Limited has been removed from the S&P/ASX 200 Index effective prior to the open of trading on Monday, June 22, 2026, according to the S&P Dow Jones Indices June...
Top Stock Reports
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Subscribe
Want more Free Research?
Subscribe today for free and get an alert when we have new research and webinars.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Contact
Get In Touch
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000